Pennsylvania Moves to Allow Medical Cannabis in Hospitals

Pennsylvania's House of Representatives has passed legislation that would guarantee terminally ill patients the right to use medical cannabis in hospitals, nursing homes, and assisted living facilities. House Bill 2254, approved in a 174-to-27 vote, now moves to the Senate in what could become one of the most significant expansions of medical cannabis patient rights in any state this year.

The bill addresses a problem that has quietly affected thousands of seriously ill patients: even in states with established medical cannabis programs, patients who enter hospitals or long-term care facilities often lose access to the medicine their doctors have certified them to use. Pennsylvania's legislation aims to close that gap for the patients who arguably need it most.

What the Bill Does

HB 2254, informally known as Ryan's Law, would require health care facilities, long-term care nursing facilities, assisted living residences, and personal care homes to allow terminally ill patients to use or be administered medical marijuana, provided several conditions are met.

The patient must hold a valid medical marijuana certification under Pennsylvania's existing program. The cannabis use must not interfere with the patient's broader treatment plan. And if marijuana is vaporized, it must be done in a manner that does not impact care provided to other patients — essentially requiring that vaporization occur in private rooms or designated spaces rather than in shared wards.

The bill was filed by State Representative Dan Frankel, a Democrat from Allegheny County, and attracted 20 additional Democratic co-sponsors. The 174-to-27 vote margin demonstrates substantial bipartisan support, with the majority of Republican members joining Democrats in favor.

What the Bill Does Not Do

The legislation is carefully scoped to avoid several potential objections. Facilities would not be required to provide medical marijuana certifications, include cannabis in discharge planning, or administer marijuana themselves. The obligation is limited to allowing patients and their designated caregivers to bring certified medical cannabis products into the facility and use them in accordance with the patient's existing medical marijuana authorization.

Several facility types are explicitly excluded. Emergency departments, psychiatric hospitals, behavioral health crisis centers, medical detoxification facilities, and residential drug and alcohol rehabilitation programs would not be subject to the requirements. This carve-out reflects practical concerns about cannabis use in settings where patients may be in acute crisis or where substance use management is a primary treatment goal.

The bill also includes a timeframe for implementation. Covered facilities would have 180 days from the law's enactment to develop internal safety guidelines and staff protocols. The Department of Health, working with the Department of Human Services, would be required to create sample guidelines and hold at least five educational sessions for facility administrators and staff.

Why This Matters for Patients

The problem HB 2254 addresses is more common than many people realize. Pennsylvania's medical marijuana program serves over 450,000 registered patients who use cannabis for conditions including cancer, chronic pain, PTSD, and neurological disorders. When these patients are hospitalized — whether for their qualifying condition or for unrelated medical issues — they typically cannot use their medical cannabis.

Hospital policies generally prohibit cannabis on facility premises, citing federal law and institutional liability concerns. For a patient with a terminal cancer diagnosis who has been using medical cannabis to manage pain, nausea, and appetite loss, entering the hospital means abruptly losing access to a medication that may have been central to their quality of life.

The consequences can be significant. Patients may experience a return of severe symptoms that cannabis was effectively managing. They may be switched to pharmaceutical alternatives — often opioids — that carry their own risks and side effects. And for patients at the end of life, the disruption compounds an already difficult experience.

"This is about dignity," Representative Frankel stated during floor debate. "When someone is facing a terminal diagnosis and has found relief through a medicine this state has recognized as legitimate, we should not force them to choose between hospital care and that relief."

Liability Protections and Enforcement

One reason the bill attracted broad support is its balanced approach to the concerns of healthcare facilities. HB 2254 includes explicit liability protections for facilities and their employees who act in good faith to comply with the law. A nurse who assists a patient with their medical cannabis use, or an administrator who develops a facility policy permitting it, would be shielded from professional discipline or civil liability.

On the enforcement side, the bill establishes civil penalties of up to $500 per violation per day for facilities that fail to comply with the chapter or its associated regulations. This penalty structure is modest enough to avoid placing undue burden on facilities while creating a meaningful incentive for compliance.

The enforcement mechanism also implicitly recognizes that implementation will not be instantaneous. The 180-day window for developing guidelines, combined with the requirement for state-sponsored educational sessions, signals a legislative intent to support facilities through the transition rather than punishing them for initial uncertainty about how to operationalize the new requirements.

The Federal Complication

The timing of HB 2254 intersects with broader federal changes that may ease some of the institutional barriers to in-facility cannabis use. The April 2026 rescheduling of state-licensed medical marijuana to Schedule III under the Controlled Substances Act reduces, though does not eliminate, the federal legal risk that hospitals have cited as a primary reason for prohibiting cannabis on their premises.

Under Schedule I classification, hospitals could argue — with some justification — that permitting any cannabis use on their premises exposed them to potential federal enforcement action, however unlikely. Schedule III classification, which applies to substances like anabolic steroids and ketamine that are routinely used in hospital settings, largely neutralizes that argument.

However, the rescheduling order's application to hospital settings has not been tested, and many healthcare systems maintain institutional policies that go beyond what federal law requires. Even with HB 2254 in place, implementation may face resistance from facilities that are cautious about changing long-standing policies.

What the Senate Will Do

The bill now moves to the Pennsylvania Senate, where its prospects are uncertain but promising. The overwhelming House margin — 174 to 27 — provides strong evidence of broad legislative support, and the bill's narrow focus on terminally ill patients makes it a politically safe vote for legislators who might otherwise be wary of expanding cannabis access.

Governor Josh Shapiro, a Democrat, has been supportive of medical cannabis expansion during his tenure, signing previous legislation that broadened qualifying conditions and expanded patient access. A bill focused on terminally ill patients is unlikely to face gubernatorial opposition if it reaches his desk.

The Senate may introduce amendments, particularly around the scope of covered facilities or the specifics of the implementation timeline. But the core principle — that terminally ill patients should not lose access to their certified medical cannabis when they enter a healthcare facility — appears to command broad support across party lines.

A Model for Other States

If enacted, Pennsylvania's law would join a small but growing number of state-level protections for medical cannabis patients in institutional care settings. New Mexico, New Hampshire, and Maine have enacted similar provisions with varying scope and requirements.

The Pennsylvania model is notable for its balance between patient access and facility autonomy. It does not require facilities to provide or administer cannabis, does not apply to settings where cannabis use could conflict with treatment goals, and includes both liability protections and enforcement mechanisms.

For the roughly 3.7 million registered medical cannabis patients across the country, the passage of HB 2254 through the Pennsylvania House represents a meaningful step toward ensuring that legal medical cannabis access does not evaporate at the hospital door. For terminally ill patients specifically, it is a recognition that comfort and dignity at the end of life should not be contingent on whether you are at home or in a care facility.

The Senate should act on this bill promptly. The patients it aims to serve do not have time to wait.